Trial Profile
Non-randomised Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA- Related Overgrowth
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Growth disorders
- Focus Therapeutic Use
- Acronyms PROMISE
- 15 Apr 2016 Status changed from recruiting to completed.
- 13 May 2015 New trial record